Provided by Tiger Fintech (Singapore) Pte. Ltd.

InflaRx N.V.

1.65
-0.0800-4.62%
Post-market: 1.59-0.0635-3.85%19:40 EDT
Volume:259.25K
Turnover:433.49K
Market Cap:111.54M
PE:-2.04
High:1.85
Open:1.75
Low:1.62
Close:1.73
Loading ...

InflaRx NV expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
Yesterday

InflaRx to Report First Quarter 2025 Results on May 7, 2025

GlobeNewswire
·
30 Apr

InflaRx Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
29 Apr

InflaRx N.V. Announces 2025 Annual General Meeting Agenda

TIPRANKS
·
03 Apr

InflaRx Is Maintained at Buy by Guggenheim

Dow Jones
·
26 Mar

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
26 Mar

InflaRx Nv : Guggenheim Raises Target Price to $10 From $7

THOMSON REUTERS
·
26 Mar

Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX), Eli Lilly & Co (LLY) and Incyte (INCY)

TIPRANKS
·
25 Mar

InflaRx Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Mar

InflaRx N.V. Reports 2024 Results and Key Achievements

TIPRANKS
·
21 Mar

InflaRx NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
20 Mar

InflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year

TIPRANKS
·
20 Mar

InflaRx's Cash, Cash Equivalents, And Marketable Securities Were €55.2M As Of December 31, 2024, Additional €28.7 Million (~$30M) In Gross Proceeds Subsequently Raised By An Underwritten Public Offering Extending Cash Runway Into 2027

Benzinga
·
20 Mar

InflaRx FY 2024 GAAP EPS €(0.78) Beats €(0.95) Estimate, Sales €165.79K Miss €306.80K Estimate

Benzinga
·
20 Mar

Press Release: InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Dow Jones
·
20 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
20 Mar

InflaRx NV expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
18 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

InflaRx Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
08 Mar

InflaRx announces presentation of multiple posters on utility of vilobelimab

TIPRANKS
·
07 Mar